Sangamo Therapeutics, Inc
Sangamo Therapeutics is a U.S.-based genomic medicine company focused on developing therapies and enabling technologies built around zinc finger biology, epigenetic regulation, and engineered AAV capsids. Its business combines internal research programs in neurological and genetic diseases with out-licensing and collaboration agreements with large biopharmaceutical partners.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueInternal drug-development programs targeting serious neurological and genetic diseases.
Licenses for the STAC-BBB capsid platform used to deliver genomic medicines to the CNS.
Partner-funded research, development support, and related collaboration services.
Upfront fees, development/commercial milestones, and potential future royalties.
Customers
Sangamo sells primarily to large biopharmaceutical companies through collaboration and license agreements, while also advancing its own therapeutic programs toward regulatory approval and eventual commercialization. Its partner base includes companies such as Lilly, Genentech, Astellas, Pfizer, and historically Kite, reflecting a business model centered on external validation and shared development economics. The company also engages with patient communities and regulators as it develops therapies for rare and serious diseases.
Buy platform licenses, target rights, and research collaboration access to Sangamo's technologies.
License STAC-BBB and related capsid technologies for CNS delivery applications.
Patients, investigators, and advocacy groups that support trial enrollment and program design.
May license or co-develop late-stage assets for commercialization and market access.
Strategy
Sangamo's strategy is to monetize its technology platforms through partnerships while advancing selected internal programs toward clinical and regulatory milestones. The company is prioritizing CNS delivery, Fabry disease readiness, and other neurology-focused opportunities where its zinc finger and capsid technologies may create differentiated value. It also seeks additional collaborations and financing to support development and preserve optionality across its pipeline.
A late-stage submission can create a path to commercialization and partner interest.
STAC-BBB licensing can generate upfront fees and future milestones while validating the platform.
Broader neurology programs increase the number of shots on goal and partnering opportunities.
Geography
Sangamo is headquartered in the United States and conducts its research, development, and corporate activities primarily from U.S. operations. Its collaborations and licensing arrangements are global in scope, with partners that operate across the U.S., Europe, and other major pharmaceutical markets. Because the company is still development-focused, geography matters mainly through regulatory pathways, partner locations, and access to capital rather than through product sales concentration.
Risks
Sangamo faces substantial financing, clinical development, and regulatory risk because it is a pre-commercial biotechnology company with long-duration R&D needs. Its revenue depends heavily on collaboration timing and partner decisions, while its ability to continue operations depends on raising additional capital. It also faces FDA approval risk, Nasdaq listing risk, and the possibility that its programs or platform technologies do not achieve expected clinical or commercial outcomes.
- Going concern and financing dependenceImpact: CriticalLikelihood: High
The company needs substantial additional capital to fund R&D and operations.
Exposure: All programs and corporate continuity
- Collaboration revenue concentration and volatilityImpact: HighLikelihood: High
Revenue is driven by upfront fees, milestones, and partner reimbursements that can end or fluctuate.
Exposure - Clinical and regulatory executionImpact: HighLikelihood: High
Approval depends on trial data, endpoint acceptance, and FDA review outcomes.
Exposure: Fabry BLA and CNS programs
- Nasdaq Capital Market complianceImpact: HighLikelihood: High
Delisting would reduce trading liquidity and could further constrain financing options.
Exposure: Common stock listing
- Macroeconomic and capital market conditionsImpact: MediumLikelihood: High
Biotech financing is sensitive to market risk appetite, rates, and sector sentiment.
Exposure
Accounting
Judgemental itemsUpfront fees, research services, and milestones are recognized over different periods and can create volatility.
Impact: Drives quarter-to-quarter revenue swings
Asset recoverability depends on future program and facility use assumptions.
Impact: Can create non-cash charges in operating expenses
Liquidity assumptions determine whether the company can continue as a going concern.
Impact: Material disclosure for investors and lenders
A significant portion of compensation expense is non-cash and affects operating loss.
Impact: Impacts reported R&D and G&A expense
Similar listed companies
Publicly listed companies with a comparable business focus.
Metagenomi Therapeutics, Inc.
MGX · Biological Products, (No Diagnostic Substances)
Relay Therapeutics, Inc.
RLAY · Biological Products, (No Diagnostic Substances)
Tango Therapeutics, Inc.
TNGX · Pharmaceutical Preparations
Gain Therapeutics, Inc.
GANX · Pharmaceutical Preparations
Mustang Bio, Inc
MBIO · Pharmaceutical Preparations
Axsome Therapeutics, Inc.
AXSM · Pharmaceutical Preparations
Axsome Therapeutics is a U.S.-based biopharmaceutical company focused on central nervous system (CNS) disorders, with a commercial portfolio built around AUVELITY, SUNOSI, and SYMBRAVO.
Last updated: 24/09/2026